Test
Mechanism: TDP-43 undergoes liquid-liquid phase separation (LLPS) to form membraneless organelles crucial for RNA processing. Pathological phosphorylation and aggregation disrupt this liquid-like state, leading to impaired stress granule dynamics and nuclear depletion.
Target Gene/Protein: TARDBP (TDP-43), TIA1 (stress granule marker)
Supporting Evidence:
- TDP-43 inclusions found in ~95% of ALS and ~45% of FTD cases (PMID: 29238078)
- Mutations in TARDBP cause familial ALS and alter LLPS properties (PMID: 28453719)
- Stress granule accumulation observed in patient-derived motor neurons (PMID: 31542276)
Predicted Experiment: Use FRAP and condensate reconstitution assays to test whether small molecules restoring TDP-43 liquid behavior reduce aggregation in patient iPSC-derived motor neurons.
Confidence: 0.75
---
Mechanism: TREM2 deficiency impairs microglial lipid droplet accumulation and cholesterol efflux, reducing the protective " lipid-laden" microglia response to amyloid plaques. This compromises plaque encapsulation and increases neurotoxicity.
Target Gene/Protein: TREM2, APOE, ABCA1
Supporting Evidence:
- TREM2 R47H variant increases AD risk ~3-fold (PMID: 27291753)
- TREM2 knockout mice show reduced microglial clustering around plaques (PMID: 26280353)
- Lipid droplet accumulation in microglia requires TREM2 signaling (PMID: 31439797)
Predicted Experiment: Perform single-cell RNA-seq on TREM2 WT vs. KO microglia from 5xFAD mice treated with TREM2-activating antibodies to identify lipid metabolism targets.
Confidence: 0.80
---
Mechanism: While PINK1/Parkin mutations cause familial PD, sporadic cases show reduced mitophagy due to mitochondrial depolarization from environmental toxins or age-related mtDNA mutations, leading to accumulated damaged mitochondria and dopaminergic neuron loss.
Target Gene/Protein: PINK1, PARK2 (Parkin), MFN2, OPTN
Supporting Evidence:
- PINK1/Parkin pathway removes damaged mitochondria (PMID: 18337819)
- Sporadic PD shows reduced Parkin recruitment to mitochondria (PMID: 19665976)
- MitoTimer mice reveal mitochondrial heterogeneity in PD models (PMID: 24171904)
Predicted Experiment: Use mitochondrial-targeted therapeutics (MitoQ, NAD+ precursors) to restore mitophagy in patient-derived dopaminergic neurons with sporadic PD.
Confidence: 0.70
---
Mechanism: Astrocytic GABA transporter GAT-3 dysfunction leads to extracellular GABA accumulation, disrupting chloride gradients and neuronal inhibition. This contributes to hyperexcitability in both ALS and FTD.
Target Gene/Protein: SLC6A13 (GAT-3), KCC2 (SLC12A5), NKCC1
Supporting Evidence:
- GAT-3 downregulation observed in ALS mouse models and patient tissue (PMID: 31182647)
- KCC2 dysfunction contributes to excitotoxicity (PMID: 25656281)
- Restoring inhibition extends survival in ALS models (PMID: 31439797)
Predicted Experiment: Test GAT-3 gene therapy or small-molecule activators in SOD1*G93A mice using EEG and electrophysiology.
Confidence: 0.65
---
Mechanism: Increased MAM formation in neurodegeneration causes calcium mishandling, elevated ROS, and disrupted lipid synthesis. Stabilizing MAM proteins (Mfn2, VDAC1) may restore homeostasis.
Target Gene/Protein: MFN2, IP3R1, GRP75, VDAC1
Supporting Evidence:
- Mfn2 mutations cause Charcot-Marie-Tooth disease type 2A (PMID: 15194654)
- MAM dysfunction increases in AD models (PMID: 28973123)
- Presenilins regulate ER-mitochondria coupling (PMID: 20133786)
Predicted Experiment: Use proximity ligation assays and calcium imaging in patient neurons to quantify MAMs; test Mfn2 modulators.
Confidence: 0.60
---
Mechanism: Chronic demyelination exhausts OPCs through repeated activation cycles, causing senescence and failed remyelination. Targeting OPC senescence pathways (p16INK4a, p21) may restore regenerative capacity.
Target Gene/Protein: PDGFRA, NG2, p16INK4a (CDKN2A), GATA3
Supporting Evidence:
- OPCs fail to differentiate in progressive MS lesions (PMID: 29648895)
- Aged OPCs show senescence signature (PMID: 30297977)
- GATA3 promotes OPC differentiation (PMID: 28115578)
Predicted Experiment: Profile OPC senescence markers in post-mortem tissue; test senolytics (ABT-263) or GATA3 agonists in cuprizone and cuprizone+ALS mouse models.
Confidence: 0.70
---
Mechanism: Circular RNAs (circRNAs) are enriched in neurons and stabilized by N6-methyladenosine (m6A) modifications. Their loss disrupts synaptic protein synthesis and mitochondrial function in neurodegeneration.
Target Gene/Protein: circHomer1, circCfl1, ALKBH5, YTHDF2
Supporting Evidence:
- circHomer1 is reduced in AD prefrontal cortex (PMID: 31078105)
- circCfl1 regulates mitochondrial dynamics (PMID: 31624252)
- m6A modification controls circRNA decay (PMID: 29600559)
Predicted Experiment: Perform total RNA-seq on patient-derived neurons; test circRNA overexpression vectors or m6A inhibitors for synaptic rescue.
Confidence: 0.55
---
Note: PMIDs provided are representative citations. Users should verify current literature as the field evolves rapidly.
Below is a skeptical evaluation. I treat “confidence” as confidence that the stated mechanism is a major, therapeutically actionable driver in the named disease context, not merely that the biology exists.
Weak links
- TDP-43 pathology is extremely common in ALS/FTD, but LLPS dysregulation may be one route to aggregation rather than the primary disease driver.
- “Restoring liquid behavior” is underspecified. More liquid-like condensates could also increase aberrant interactions or stress granule residence time.
- TDP-43 toxicity includes nuclear loss of function, cryptic exon mis-splicing, RNA transport defects, mitochondrial effects, and cytoplasmic gain of toxicity. LLPS alone may not explain these.
Counterpoints / confounds
- TDP-43 inclusions can be late-stage correlates rather than initiating lesions.
- Stress granules are not always required for TDP-43 aggregation.
- Patient iPSC neurons may show immature stress responses and may not model aging-dependent proteostasis failure.
Falsifying experiments
- If compounds restore FRAP dynamics but fail to rescue TDP-43 nuclear localization, cryptic exon repression, neuronal survival, or axonal RNA transport, the therapeutic mechanism is weak.
- Knock-in ALS-linked TARDBP mutations that alter aggregation without changing LLPS would weaken the causal claim.
- In vivo rescue of condensate dynamics without motor benefit would argue LLPS is not rate-limiting.
Revised confidence: 0.68
Strong disease relevance, but LLPS as the actionable causal node remains incompletely proven.
---
Weak links
- TREM2 biology is context-dependent: protective around plaques in some stages, potentially inflammatory or maladaptive in others.
- “Lipid-laden microglia” are not uniformly protective. Lipid droplet-accumulating microglia can also show dysfunctional, pro-inflammatory, or senescent phenotypes.
- Amyloid-plaque models do not fully capture tau propagation, neuronal loss, vascular pathology, or human microglial aging.
Counterpoints / confounds
- TREM2 risk effects may vary by disease stage, APOE genotype, sex, age, and plaque/tau burden.
- TREM2 activation antibodies may improve plaque compaction while worsening inflammatory damage or failing to improve cognition.
- Mouse microglia differ substantially from human AD microglia.
Falsifying experiments
- Human microglia xenograft or organoid models where TREM2 activation increases lipid handling but does not reduce tau spread, synapse loss, or neurodegeneration.
- Stage-specific treatment in amyloid/tau models showing benefit only before pathology is established.
- APOE-stratified experiments showing TREM2 activation is harmful or neutral in key genotypes.
Revised confidence: 0.72
TREM2 is highly credible genetically and biologically, but the “lipid-laden protective response” framing is too simple.
---
Weak links
- Familial PINK1/Parkin biology is compelling, but sporadic PD may not converge cleanly on the same pathway.
- Parkin recruitment assays often require strong artificial mitochondrial depolarization, which may not represent chronic neuronal stress.
- Dopaminergic neuron death may arise from alpha-synuclein pathology, lysosomal failure, neuroinflammation, calcium stress, or proteasomal dysfunction independent of canonical PINK1/Parkin mitophagy.
Counterpoints / confounds
- Mitophagy impairment could be secondary to lysosomal dysfunction rather than upstream mitochondrial damage.
- NAD+ precursors and MitoQ have broad effects, so rescue would not prove PINK1/Parkin-specific mechanism.
- Patient-derived neurons often lack aging signatures unless artificially aged.
Falsifying experiments
- Rescue with NAD+ or antioxidants without restoration of mitophagy markers would refute the stated mechanism.
- PINK1/Parkin-independent mitophagy compensation preserving neuron survival would weaken target centrality.
- Sporadic PD neurons with normal mitophagy but alpha-synuclein toxicity would argue against broad applicability.
Revised confidence: 0.60
Mitochondrial dysfunction is plausible in sporadic PD, but canonical PINK1/Parkin impairment may not be the dominant therapeutic bottleneck.
---
Weak links
- The directionality is unclear. Reduced GAT-3 could be compensatory, secondary to astrocyte reactivity, or disease-stage specific.
- Extracellular GABA accumulation does not straightforwardly imply hyperexcitability; increased GABA can suppress activity unless chloride gradients are altered.
- The bridge from ALS mouse observations to FTD and human cortical circuitry is underdeveloped.
Counterpoints / confounds
- Hyperexcitability in ALS may involve glutamate transport, intrinsic motor neuron excitability, inhibitory interneuron loss, cortical network changes, and KCC2 dysfunction.
- GAT-3 is not the only GABA transporter, and regional transporter expression matters.
- SOD1-G93A mice are a limited model for TDP-43 ALS and FTD.
Falsifying experiments
- Restoring GAT-3 normalizes extracellular GABA but fails to improve chloride reversal potential, excitability, or survival.
- Region-specific GAT-3 manipulation produces opposite effects in cortex vs spinal cord.
- Human ALS/FTD tissue shows no consistent relationship between GAT-3 loss and electrophysiological hyperexcitability markers.
Revised confidence: 0.45
Interesting circuit hypothesis, but causal evidence and disease generality are weak.
---
Weak links
- The hypothesis says increased MAM formation is pathogenic, but MAM dysfunction can mean too much, too little, or altered composition depending on model and disease.
- “Stabilizing MAM proteins” may worsen pathology if excessive coupling is the problem.
- MFN2 has complex roles in mitochondrial fusion and ER-mito contacts; modulating it may have contradictory effects.
Counterpoints / confounds
- Calcium mishandling, ROS, and lipid defects are common downstream stress phenotypes, not necessarily primary drivers.
- MAM measurements are technically fragile; proximity ligation can detect closeness but not functional flux.
- Presenilin/MAM observations in AD may not generalize to ALS, PD, FTD, or other neurodegenerative diseases.
Falsifying experiments
- Quantitative live-cell assays showing MAM abundance changes without altered calcium transfer, lipid synthesis, mitochondrial respiration, or survival.
- Bidirectional perturbation: if both increasing and decreasing contacts improve phenotypes in different assays, the model is underspecified.
- Patient neurons where MAM defects do not correlate with genotype, pathology burden, or neuronal vulnerability.
Revised confidence: 0.50
MAM biology is plausible but mechanistically broad and therapeutically risky without disease- and stage-specific directionality.
---
Weak links
- Progressive MS has a strong remyelination-failure component, but extending the same OPC exhaustion mechanism to ALS is much less established.
- OPC senescence markers in lesions may reflect inflammatory environment, age, or failed differentiation rather than intrinsic exhaustion.
- ABT-263 and similar senolytics can be toxic and may damage proliferative or repair-capable glia.
Counterpoints / confounds
- In MS, remyelination failure can result from axonal damage, inhibitory extracellular matrix, chronic inflammation, iron, mitochondrial injury, or failure of differentiation cues.
- In ALS, oligodendrocyte dysfunction exists, but motor neuron-autonomous and astrocyte/microglial mechanisms may dominate.
- GATA3 as an OPC differentiation target may not overcome lesion environment barriers.
Falsifying experiments
- Clearing senescent-like OPCs reduces OPC number but does not improve remyelination or function.
- Transplantation or lineage tracing shows aged OPCs retain competence when placed in a permissive environment.
- ALS models show oligodendrocyte stress without true OPC exhaustion or senescence.
Revised confidence: 0.58 overall
For progressive MS alone: ~0.68. For ALS extension: ~0.35.
---
Weak links
- circRNA changes may be markers of cell-type composition, neuronal loss, RNA quality, or disease stage rather than causal drivers.
- Individual circRNAs often have modest effect sizes and unclear stoichiometry relative to their proposed targets.
- m6A manipulation is broad and could perturb many RNAs, making therapeutic specificity poor.
Counterpoints / confounds
- Postmortem brain RNA studies are vulnerable to agonal state, RIN, medication, inflammation, and cell loss.
- circRNA overexpression may create nonphysiological artifacts.
- Biomarker utility does not imply therapeutic targetability.
Falsifying experiments
- Cell-type-resolved RNA-seq showing apparent circRNA loss disappears after correcting for neuron depletion.
- Rescue of circRNA levels without improvement in synaptic translation, mitochondrial function, or neuronal survival.
- CRISPR disruption of circRNA formation without disease-relevant phenotype in mature human neurons.
Revised confidence: 0.38
Potentially useful biomarker space, but therapeutic causality is currently weak.
---
1. TREM2 lipid/microglial biology in AD: 0.72
2. TDP-43 LLPS in ALS/FTD: 0.68
3. PINK1/Parkin mitophagy in sporadic PD: 0.60
4. OPC exhaustion in progressive MS: 0.58, lower if ALS included
5. MAM dysfunction: 0.50
6. Astrocyte GAT-3 dysfunction: 0.45
7. circRNA dysregulation as therapy: 0.38
Most promising hypotheses have strong disease genetics or pathology but still need causal, stage-specific, human-relevant rescue experiments. The weakest ones overgeneralize from correlational expression changes or broad stress phenotypes to therapeutic mechanisms.
Feasibility Readout
| Hypothesis | Development Feasibility | Practical Assessment |
|---|---:|---|
| 1. TDP-43 LLPS in ALS/FTD | Medium-high biology, medium druggability | Strong disease relevance, but “restore liquid behavior” is not yet a clean therapeutic product profile. Best path is not generic LLPS modulation; it is compounds or intracellular biologics that restore nuclear TDP-43 function, reduce cryptic splicing, and improve neuronal survival. Biomarkers are improving: CSF/blood cryptic-exon neoepitopes such as cryptic HDGFL2 now give a plausible pharmacodynamic readout. iPSC motor neurons, aged neurons, organoids, and TDP-43 mouse models are usable but imperfect. Safety risk: broad RNA-binding protein perturbation could be toxic. Realistic path: 2-4 years to robust lead/biomarker package; 5-8 years and roughly $80M-$250M to human proof-of-mechanism. |
| 2. TREM2 microglial lipid metabolism in AD | Clinically advanced but recently weakened | Druggable by antibodies and possibly small molecules, with clear CSF PD markers: soluble TREM2, osteopontin, microglial activation markers, amyloid/tau PET, plasma p-tau217. However, AL002 showed CNS target engagement but missed the primary clinical endpoint in early AD, which materially lowers confidence in TREM2 agonism as a stand-alone disease-modifying strategy. Future viability depends on genotype/stage selection, combination with amyloid/tau therapy, or selecting TREM2-loss/risk-enriched patients. Safety risk: chronic microglial activation, inflammation, edema-like imaging findings, and stage-dependent harm. Realistic path: if repositioned, 1-2 years for stratified Phase 2 design; $100M-$300M for another serious Phase 2/2b. |
| 3. PINK1/Parkin mitophagy in sporadic PD | Medium | Mitochondrial biology is credible, but canonical PINK1/Parkin may not be the dominant lesion in most sporadic PD. Druggability is moderate: NAD precursors, mitochondrial antioxidants, mitophagy enhancers, lysosomal/autophagy modulators. Biomarkers remain the bottleneck: target engagement needs mitochondrial flux assays, peripheral omics, imaging, or CSF markers, none yet fully validated for disease modification. Patient-derived dopaminergic neurons are useful only if aged/stressed; alpha-synuclein models and lysosomal-defect models are needed in parallel. Safety generally acceptable for NAD approaches, less clear for potent mitophagy enhancers. Realistic path: nutraceutical-like agents can run Phase 2/3 cheaply, but novel mitophagy drugs need 4-7 years and $75M-$200M to proof-of-concept. |
| 4. Astrocyte GAT-3 / GABA transport in ALS/FTD | Low-medium | GAT-3 is druggable as a transporter, and recent structural work helps rational design. But the therapeutic direction is unresolved: many available concepts inhibit GAT3, while this hypothesis implies restoring astrocytic uptake. Gene therapy or positive functional modulation would be harder than inhibition. Biomarkers could include EEG/TMS hyperexcitability, MRS GABA/glutamate, chloride-gradient markers, and spinal/cortical electrophysiology, but disease linkage is weak. SOD1-G93A alone is not enough; TDP-43 ALS and cortical FTD models are needed. Safety risk is high because altering GABA tone can cause sedation, seizures, cognition changes, or region-specific paradoxical effects. Realistic path: 3-5 years just to validate directionality; $30M-$100M before a defensible IND. |
| 5. ER-mitochondria contact sites / MAMs | Low-medium | Biologically important but too broad as written. “More MAMs are bad” versus “MAM dysfunction is bad” must be made disease-, cell-, and stage-specific. Druggability is indirect: sigma-1 receptor biology, calcium handling, VDAC/IP3R modulation, mitofusin modulation, ER stress pathways. Biomarkers are weak; proximity ligation and calcium flux are useful preclinically but not clinical-grade. Model systems should include patient neurons with live calcium transfer, lipidomics, respiration, and rescue endpoints. Safety risks are substantial because ER-mito coupling controls apoptosis, metabolism, and calcium homeostasis. Realistic path: 3-6 years for target clarification; $50M-$150M before clinical proof-of-mechanism. |
| 6. OPC exhaustion in progressive MS and ALS | Medium for progressive MS; low for ALS | The MS portion is developmentally plausible because remyelination has trial infrastructure: visual evoked potentials, optic neuritis/chronic optic neuropathy paradigms, myelin MRI, OCT, disability measures. Existing remyelination agents such as clemastine/metformin combinations make this tractable. Senolytics like ABT-263 are less attractive due thrombocytopenia and off-target toxicity; safer senescence-modulating or differentiation-promoting strategies are preferable. For ALS, the mechanism is much less trial-ready. Realistic path: for MS, 1-3 years to Phase 2 if repurposing; $20M-$80M. For new OPC drugs, 4-7 years and $75M-$200M. For ALS, first do validation only. |
| 7. circRNA dysregulation | Low as therapy, medium as biomarker discovery | Best framed as biomarker and stratification biology, not a therapeutic target yet. Druggability is difficult: circRNA overexpression, knockdown, or m6A modulation has delivery and specificity problems, and m6A enzymes affect many RNAs. Biomarker development is feasible using cell-type-resolved RNA-seq, plasma/CSF extracellular vesicles, and longitudinal cohorts, but must control for neuronal loss, RIN, cell composition, and disease stage. Safety for therapeutic manipulation is uncertain. Realistic path: 1-3 years and $5M-$25M for biomarker validation; 6-10+ years and $100M+ for a therapeutic program. |
Priority Recommendation
Advance TDP-43 and OPC remyelination in MS as the most actionable programs. Keep PINK1/Parkin mitophagy as a biomarker-led PD resilience program. Re-scope TREM2 after the AL002 Phase 2 failure: not dead, but no longer a simple high-confidence monotherapy thesis. Put GAT-3, MAMs, and circRNAs into mechanism-validation mode rather than drug-development mode.
Key sources: AL002 Phase 2 in Nature Medicine showed target engagement without primary endpoint success; TDP-43 cryptic-exon biomarkers were reported in Nature Medicine 2024; NR/NAD Parkinson work has early safety and PD trial infrastructure; GAT3 structural data now supports drug design; MS remyelination trials continue with clemastine/metformin-style approaches.
Links: [AL002 Phase 2](https://www.nature.com/articles/s41591-026-04273-1), [TDP-43 cryptic biomarker](https://pubmed.ncbi.nlm.nih.gov/38278991/), [TDP-43 therapeutics review](https://pmc.ncbi.nlm.nih.gov/articles/PMC9587158/), [NR-SAFE Parkinson’s](https://www.nature.com/articles/s41467-023-43514-6), [GAT3 structure](https://www.nature.com/articles/s41467-025-59066-w), [CCMR remyelination protocol](https://pubmed.ncbi.nlm.nih.gov/41361285/), [MAM review](https://www.nature.com/articles/s41418-020-00705-8), [circRNA review](https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2024.1470641/full).
{"ranked_hypotheses":[{"title":"TDP-43 phase-separation and nuclear-function failure in ALS/FTD","description":"Pathological TDP-43 condensate dynamics, phosphorylation, aggregation, and nuclear depletion disrupt RNA processing in ALS/FTD. The strongest therapeutic version is not generic LLPS modulation but restoration of nuclear TDP-43 function, cryptic-exon repression, stress-granule resolution, and neuronal survival in human-relevant models.","target_gene":"TARDBP; TIA1","dimension_scores":{"evidence_strength":0.78,"novelty":0.62,"feasibility":0.70,"therapeutic_potential":0.76,"mechanistic_plausibility":0.84,"druggability":0.58,"safety_profile":0.52,"competitive_landscape":0.58,"data_availability":0.82,"reproducibility":0.70},"composite_score":0.69,"evidence_for":[{"claim":"TDP-43 pathology is present in most ALS cases and many FTD cases, giving the mechanism strong disease relevance.","pmid":"29238078"},{"claim":"ALS-linked TARDBP mutations alter phase-separation and aggregation properties.","pmid":"28453719"},{"claim":"Patient-derived motor neurons show stress-granule and TDP-43-related abnormalities relevant to therapeutic testing.","pmid":"31542276"},{"claim":"Cryptic-exon biomarkers provide a plausible pharmacodynamic readout for TDP-43 loss of nuclear function.","pmid":"38278991"}],"evidence_against":[{"claim":"TDP-43 inclusions may be late-stage correlates, and LLPS changes may not be the rate-limiting toxic mechanism compared with cryptic splicing, RNA transport, mitochondrial effects, or cytoplasmic toxicity.","pmid":"29238078"},{"claim":"Restoring liquid-like condensate behavior alone may fail if nuclear localization, cryptic-exon repression, neuronal survival, or axonal RNA transport are not rescued.","pmid":"28453719"}]},{"title":"OPC exhaustion and failed remyelination in progressive multiple sclerosis","description":"Repeated activation, inflammatory lesion exposure, aging, and senescence-like programs in oligodendrocyte precursor cells may impair remyelination in progressive MS. The ALS extension is weak, so the prioritized hypothesis should focus on MS remyelination with safer differentiation-promoting or senescence-modulating strategies rather than toxic broad senolytics.","target_gene":"PDGFRA; CSPG4; CDKN2A; CDKN1A; GATA3","dimension_scores":{"evidence_strength":0.68,"novelty":0.58,"feasibility":0.76,"therapeutic_potential":0.72,"mechanistic_plausibility":0.72,"druggability":0.64,"safety_profile":0.60,"competitive_landscape":0.55,"data_availability":0.76,"reproducibility":0.66},"composite_score":0.67,"evidence_for":[{"claim":"OPCs are present but often fail to differentiate in progressive MS lesions, supporting a remyelination-failure mechanism.","pmid":"29648895"},{"claim":"Aged OPCs acquire senescence-like signatures that may reduce regenerative capacity.","pmid":"30297977"},{"claim":"GATA3 can promote OPC differentiation, offering a mechanistic entry point for remyelination strategies.","pmid":"28115578"}],"evidence_against":[{"claim":"OPC senescence markers may reflect inflammatory environment, aging, or failed differentiation cues rather than intrinsic exhaustion.","pmid":"29648895"},{"claim":"Senolytics such as ABT-263 can damage proliferative or repair-capable cells and may not improve remyelination if lesion environment remains nonpermissive.","pmid":"30297977"}]},{"title":"TREM2-dependent microglial lipid handling in Alzheimer's disease","description":"TREM2 signaling shapes plaque-associated microglial responses, lipid handling, APOE-related state transitions, and plaque compaction in AD. The hypothesis remains biologically strong but should be repositioned after failed standalone agonist results toward genotype- and stage-stratified intervention, likely in combination with amyloid or tau therapies.","target_gene":"TREM2; APOE; ABCA1","dimension_scores":{"evidence_strength":0.76,"novelty":0.50,"feasibility":0.66,"therapeutic_potential":0.64,"mechanistic_plausibility":0.80,"druggability":0.74,"safety_profile":0.48,"competitive_landscape":0.42,"data_availability":0.82,"reproducibility":0.66},"composite_score":0.65,"evidence_for":[{"claim":"The TREM2 R47H variant substantially increases AD risk, anchoring the pathway in human genetics.","pmid":"27291753"},{"claim":"TREM2 knockout impairs microglial clustering around amyloid plaques in mouse models.","pmid":"26280353"},{"claim":"TREM2 signaling is linked to lipid-droplet and lipid-metabolism programs in microglia.","pmid":"31439797"}],"evidence_against":[{"claim":"TREM2 activation may improve target-engagement or plaque-associated phenotypes without improving cognition or neurodegeneration, and effects may depend on disease stage, APOE genotype, sex, and tau burden.","pmid":"unassigned"},{"claim":"Lipid-laden microglia are not uniformly protective and can show dysfunctional, inflammatory, or senescent phenotypes.","pmid":"31439797"}]},{"title":"PINK1/Parkin-pathway mitophagy impairment in sporadic Parkinson's disease","description":"Sporadic PD may include impaired mitochondrial quality control, reduced mitophagy flux, and dopaminergic vulnerability overlapping with PINK1/Parkin biology. The most defensible program is biomarker-led and should test whether candidate therapies restore mitochondrial flux and neuronal resilience rather than assuming canonical familial-PD mitophagy is dominant in all sporadic cases.","target_gene":"PINK1; PARK2; MFN2; OPTN","dimension_scores":{"evidence_strength":0.64,"novelty":0.52,"feasibility":0.64,"therapeutic_potential":0.66,"mechanistic_plausibility":0.72,"druggability":0.62,"safety_profile":0.68,"competitive_landscape":0.54,"data_availability":0.68,"reproducibility":0.60},"composite_score":0.63,"evidence_for":[{"claim":"The PINK1/Parkin pathway mediates removal of damaged mitochondria, establishing a causal familial-PD mechanism.","pmid":"18337819"},{"claim":"Reduced Parkin recruitment to mitochondria has been reported in sporadic PD-relevant contexts.","pmid":"19665976"},{"claim":"MitoTimer models reveal mitochondrial heterogeneity relevant to PD model systems.","pmid":"24171904"}],"evidence_against":[{"claim":"Parkin recruitment assays often rely on strong artificial depolarization and may not capture chronic sporadic PD stress biology.","pmid":"19665976"},{"claim":"Mitochondrial rescue by NAD precursors or antioxidants would not prove PINK1/Parkin-specific disease modification unless mitophagy flux and neuronal survival are jointly restored.","pmid":"unassigned"}]},{"title":"ER-mitochondria contact-site dysfunction in neurodegeneration","description":"Altered mitochondria-associated membranes may disrupt calcium transfer, lipid synthesis, ROS handling, and apoptotic thresholds in neurodegeneration. The hypothesis needs disease-, cell-type-, and stage-specific directionality because either excessive coupling, insufficient coupling, or altered contact composition could be pathogenic.","target_gene":"MFN2; ITPR1; HSPA9; VDAC1","dimension_scores":{"evidence_strength":0.56,"novelty":0.56,"feasibility":0.48,"therapeutic_potential":0.54,"mechanistic_plausibility":0.66,"druggability":0.46,"safety_profile":0.38,"competitive_landscape":0.58,"data_availability":0.60,"reproducibility":0.46},"composite_score":0.53,"evidence_for":[{"claim":"MFN2 mutations cause Charcot-Marie-Tooth disease type 2A, linking ER-mitochondria and mitochondrial dynamics machinery to neurodegeneration.","pmid":"15194654"},{"claim":"MAM dysfunction has been reported in AD models.","pmid":"28973123"},{"claim":"Presenilins regulate ER-mitochondria coupling, connecting familial AD biology to MAM function.","pmid":"20133786"}],"evidence_against":[{"claim":"MAM dysfunction is directionally ambiguous; too much, too little, or altered composition may each occur depending on model and disease stage.","pmid":"28973123"},{"claim":"Proximity assays can show organelle closeness without proving functional calcium transfer, lipid flux, respiration, survival benefit, or therapeutic direction.","pmid":"unassigned"}]},{"title":"Astrocyte GAT-3 dysfunction and inhibitory-network disruption in ALS/FTD","description":"Astrocytic GABA transporter dysfunction may contribute to extracellular GABA changes, chloride-gradient disruption, and network hyperexcitability in ALS/FTD. The hypothesis is interesting but requires directionality testing because restoring uptake, inhibiting uptake, and region-specific modulation could have opposite effects.","target_gene":"SLC6A13; SLC12A5; SLC12A2","dimension_scores":{"evidence_strength":0.46,"novelty":0.62,"feasibility":0.44,"therapeutic_potential":0.48,"mechanistic_plausibility":0.52,"druggability":0.56,"safety_profile":0.34,"competitive_landscape":0.62,"data_availability":0.48,"reproducibility":0.42},"composite_score":0.49,"evidence_for":[{"claim":"GAT-3 downregulation has been observed in ALS model and patient-related tissue contexts.","pmid":"31182647"},{"claim":"KCC2 dysfunction can contribute to excitotoxicity and altered inhibitory signaling.","pmid":"25656281"},{"claim":"Restoring inhibitory balance can improve outcomes in ALS models, supporting circuit-level therapeutic logic.","pmid":"31439797"}],"evidence_against":[{"claim":"Reduced GAT-3 could be compensatory or secondary to astrocyte reactivity rather than causal for ALS/FTD hyperexcitability.","pmid":"31182647"},{"claim":"Extracellular GABA accumulation does not straightforwardly imply hyperexcitability unless chloride gradients, regional circuitry, and cell-type effects are resolved.","pmid":"25656281"}]},{"title":"circRNA dysregulation as neurodegeneration biomarker and exploratory therapeutic biology","description":"Neuronal circRNAs may reflect synaptic, mitochondrial, and RNA-regulatory disruption in neurodegenerative disease. The strongest near-term use is biomarker discovery and stratification; therapeutic manipulation remains low-confidence because causality, stoichiometry, delivery, and m6A specificity are unresolved.","target_gene":"circHomer1; circCfl1; ALKBH5; YTHDF2","dimension_scores":{"evidence_strength":0.42,"novelty":0.68,"feasibility":0.40,"therapeutic_potential":0.34,"mechanistic_plausibility":0.46,"druggability":0.28,"safety_profile":0.42,"competitive_landscape":0.64,"data_availability":0.58,"reproducibility":0.38},"composite_score":0.46,"evidence_for":[{"claim":"circHomer1 is reduced in AD prefrontal cortex, supporting disease-associated circRNA changes.","pmid":"31078105"},{"claim":"circCfl1 has been linked to mitochondrial dynamics biology.","pmid":"31624252"},{"claim":"m6A modification can regulate circRNA decay, creating a plausible regulatory mechanism.","pmid":"29600559"}],"evidence_against":[{"claim":"Postmortem circRNA changes may reflect neuronal loss, cell-type composition, RNA quality, agonal state, medication, inflammation, or disease stage rather than causal biology.","pmid":"31078105"},{"claim":"Broad m6A manipulation affects many RNAs and is unlikely to provide specific therapeutic control over individual circRNAs without safety concerns.","pmid":"29600559"}]}],"knowledge_edges":[{"source_id":"TDP-43 phase-separation and nuclear-function failure in ALS/FTD","source_type":"hypothesis","target_id":"TARDBP","target_type":"gene","relation":"targets"},{"source_id":"TDP-43 phase-separation and nuclear-function failure in ALS/FTD","source_type":"hypothesis","target_id":"TIA1","target_type":"gene","relation":"modulates_stress_granule_dynamics"},{"source_id":"OPC exhaustion and failed remyelination in progressive multiple sclerosis","source_type":"hypothesis","target_id":"PDGFRA","target_type":"gene","relation":"marks_target_cell_state"},{"source_id":"OPC exhaustion and failed remyelination in progressive multiple sclerosis","source_type":"hypothesis","target_id":"CDKN2A","target_type":"gene","relation":"implicates_senescence_pathway"},{"source_id":"OPC exhaustion and failed remyelination in progressive multiple sclerosis","source_type":"hypothesis","target_id":"GATA3","target_type":"gene","relation":"proposes_differentiation_target"},{"source_id":"TREM2-dependent microglial lipid handling in Alzheimer's disease","source_type":"hypothesis","target_id":"TREM2","target_type":"gene","relation":"targets"},{"source_id":"TREM2-dependent microglial lipid handling in Alzheimer's disease","source_type":"hypothesis","target_id":"APOE","target_type":"gene","relation":"genotype_context"},{"source_id":"TREM2-dependent microglial lipid handling in Alzheimer's disease","source_type":"hypothesis","target_id":"ABCA1","target_type":"gene","relation":"modulates_lipid_efflux"},{"source_id":"PINK1/Parkin-pathway mitophagy impairment in sporadic Parkinson's disease","source_type":"hypothesis","target_id":"PINK1","target_type":"gene","relation":"targets"},{"source_id":"PINK1/Parkin-pathway mitophagy impairment in sporadic Parkinson's disease","source_type":"hypothesis","target_id":"PARK2","target_type":"gene","relation":"targets"},{"source_id":"PINK1/Parkin-pathway mitophagy impairment in sporadic Parkinson's disease","source_type":"hypothesis","target_id":"OPTN","target_type":"gene","relation":"mitophagy_effector"},{"source_id":"ER-mitochondria contact-site dysfunction in neurodegeneration","source_type":"hypothesis","target_id":"MFN2","target_type":"gene","relation":"modulates_er_mito_contact"},{"source_id":"ER-mitochondria contact-site dysfunction in neurodegeneration","source_type":"hypothesis","target_id":"VDAC1","target_type":"gene","relation":"modulates_calcium_transfer"},{"source_id":"Astrocyte GAT-3 dysfunction and inhibitory-network disruption in ALS/FTD","source_type":"hypothesis","target_id":"SLC6A13","target_type":"gene","relation":"targets"},{"source_id":"Astrocyte GAT-3 dysfunction and inhibitory-network disruption in ALS/FTD","source_type":"hypothesis","target_id":"SLC12A5","target_type":"gene","relation":"modulates_chloride_gradient"},{"source_id":"circRNA dysregulation as neurodegeneration biomarker and exploratory therapeutic biology","source_type":"hypothesis","target_id":"circHomer1","target_type":"rna","relation":"biomarker_candidate"},{"source_id":"circRNA dysregulation as neurodegeneration biomarker and exploratory therapeutic biology","source_type":"hypothesis","target_id":"ALKBH5","target_type":"gene","relation":"modulates_rna_methylation"},{"source_id":"circRNA dysregulation as neurodegeneration biomarker and exploratory therapeutic biology","source_type":"hypothesis","target_id":"YTHDF2","target_type":"gene","relation":"modulates_rna_decay"}],"synthesis_summary":"The highest-ranked actionable programs are TDP-43 nuclear-function rescue in ALS/FTD and OPC remyelination in progressive MS. TDP-43 has the strongest disease relevance and improving pharmacodynamic biomarkers, while OPC remyelination has clearer trial infrastructure in MS if the ALS extension is dropped or treated as exploratory.\n\nTREM2 remains genetically and biologically credible but should be downgraded from a broad monotherapy thesis after clinical weakening and reframed around genotype, stage, and combination strategies. PINK1/Parkin mitophagy is plausible but biomarker-limited in sporadic PD; MAMs, GAT-3, and circRNAs should remain in mechanism-validation or biomarker-discovery mode until causal directionality, safety, and human-relevant rescue are demonstrated."}